Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Raltegravir: first in class HIV integrase inhibitor

Authors Temesgen Z, Siraj DS

Published 11 April 2008 Volume 2008:4(2) Pages 493—500

DOI https://doi.org/10.2147/TCRM.S2268

Zelalem Temesgen1, Dawd S Siraj2

1Mayo Clinic, Rochester, MN, USA; 2East Carolina University Greenville, NC, USA

Abstract: On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus (HIV)-1 infection in combination with other antiretroviral agents in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. Raltegravir is first in a novel class of antiretroviral drugs known as integrase inhibitors. It has demonstrated potent anti HIV activity in both antiretroviral treatment-naïve and experienced patients. The most common adverse events reported with raltegravir during phase 2 and 3 clinical trials were diarrhea, nausea, and headache. Laboratory abnormalities include mild elevations in liver transaminases and creatine phosphokinase.

Keywords: raltegravir, HIV, antiretroviral agents, integrase inhibitors

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Five-year review of an international clinical research-training program

Suemoto CK, Ismail S, Corrêa PCRP, Khawaja F, Jerves T, Pesantez L, Germani AC, Zaina F, Santos AC, Ferreira RJ, Singh P, Paulo JV, Matsubayashi SR, Vidor LP, Andretta G, Tomás R, Illigens BM, Fregni F

Advances in Medical Education and Practice 2015, 6:249-257

Published Date: 1 April 2015

Fluoromica nanoparticle cytotoxicity in macrophages decreases with size and extent of uptake

Tee N, Zhu Y, Mortimer GM, Martin DJ, Minchin RF

International Journal of Nanomedicine 2015, 10:2363-2375

Published Date: 26 March 2015

Electrochemical sensing method for point-of-care cortisol detection in human immunodeficiency virus-infected patients

Kaushik A, Yndart A, Jayant RD, Sagar V, Atluri V, Bhansali S, Nair M

International Journal of Nanomedicine 2015, 10:677-685

Published Date: 19 January 2015

A gene expression ratio-based diagnostic test for bladder cancer

Lingsheng Dong, Andrew J Bard, William G Richards, Matthew D Nitz, Dan Theodorescu, et al

Advances and Applications in Bioinformatics and Chemistry 2009, 2:17-22

Published Date: 12 January 2009

Exemestane in early breast cancer: a review

Michael Untch, Christian Jackisch

Therapeutics and Clinical Risk Management 2008, 4:1295-1304

Published Date: 5 December 2008

Treatment of hereditary angioedema with plasma-derived C1 inhibitor

Michael J Prematta, Tracy Prematta, Timothy J Craig

Therapeutics and Clinical Risk Management 2008, 4:975-982

Published Date: 10 October 2008

Update on the treatment of ankylosing spondylitis

Walter P Maksymowych

Therapeutics and Clinical Risk Management 2007, 3:1125-1133

Published Date: 15 January 2008

Editorial || FREE PAPER ||

Garry M Walsh

Therapeutics and Clinical Risk Management 2007, 3:361-362

Published Date: 15 July 2007

Alendronate sodium in the management of osteoporosis

P J J Prinsloo, DJ Hosking

Therapeutics and Clinical Risk Management 2006, 2:235-249

Published Date: 15 September 2006